Clin2
NCT05761028Possibly a fitRecruiting

CM310 for moderate to severe asthma despite current inhalers

Moderate to Severe Asthma

Part of Lungs & breathing clinical trials.

This study tests CM310 to see if it can improve asthma in people with moderate to severe asthma who are still having uncontrolled symptoms and severe flare-ups despite regular inhaler treatment. You may be eligible if your lung function and asthma control tests fit the study limits and you’ve had a recent severe exacerbation.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2/Phase 3
Enrollment
600 people
Ages
12 years to 75 years
Study type
Interventional

Who can take part

  • You can understand the study and sign the consent form yourself (or with a legally acceptable process).
  • You are between 12 and 75 years old and weigh at least 40 kg.
  • You have had asthma for at least 1 year, and your test results match GINA 2022 criteria.
  • Your lung function is reduced at screening (FEV1 ≤ 80% of predicted), and you show bronchodilator response (bigger improvement after a rescue inhaler).
  • Despite using medium-to-high dose inhaled steroid plus other controller medicine for at least 3 months (stable for at least 1 month), your asthma control scores are still high (ACQ-5 ≥ 1.5).
  • You’ve had at least one severe asthma flare-up in the past 12 months, but none in the last month.
  • If you could become pregnant (or have a partner who could), you agree to highly effective birth control starting now and for 3 months after the last study dose.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07372287Recruiting· Phase 3
Study of CM326 for moderate to severe asthma

This trial tests an investigational drug called CM326 for people with moderate to severe asthma that is not well controlled with current treatments. It aims to see if CM326 can help reduce asthma attacks and improve breathing.

Shanghai, Shanghai Municipality
NCT07403487Not yet recruiting· Phase 2
Testing an injectable medicine for asthma

This study tests a new injected medicine (RC1416) for people with moderate-to-severe asthma that is not well controlled with daily inhalers. It may help reduce asthma attacks and improve breathing.

Suzhou, Anhui
NCT07418736Recruiting· Phase 2
CM326 for moderate to severe COPD

This trial tests a new medicine called CM326 for people with moderate to severe COPD. It aims to see if the drug can reduce flare-ups and improve lung function.

Beijing, Beijing Municipality
NCT06300203Recruiting· Phase 2
CM310 for uncontrolled seasonal allergies

This study tests a new medicine called CM310 for people whose seasonal allergies are not well controlled by their usual medications. If you join, you'll help see if this treatment can better control your allergy symptoms.

Beijing, Beijing Municipality
NCT06488755Recruiting· Phase 3
Study of an asthma treatment for people with moderate to severe asthma

This trial tests an experimental medication called SIM0718 to see if it can improve asthma control and reduce flare-ups. It may be an option for people whose asthma is not well-controlled with their current inhaler therapy.

Beijing, Beijing Municipality
NCT06547333Not yet recruiting· Phase 2/Phase 3
Study of CM310 for frequent COPD flare-ups

This study tests a new injectable medicine called CM310 for people with moderate to severe COPD who have chronic bronchitis and frequent flare-ups, despite using standard inhalers. It aims to see if CM310 can reduce flare-ups and improve breathing by targeting a specific type of inflammation.

Hear when a new Moderate to Severe Asthma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.